Spectra

Bio-Edge, Inc., established in 1993, is a San Diego-based company specializing in custom research and small-scale production of materials for medical devices and other custom material applications. With a dedicated lab for process development and production on the first floor and an R&D laboratory on the second floor capable of polymer synthesis, purification, analysis, and prototype device development and testing, Bio-Edge offers comprehensive solutions for the healthcare industry. As a leader in contract research and custom development, Bio-Edge provides services such as polymer synthesis, prototype development, and device testing. With a focus on medical device materials and applications, the company plays a crucial role in advancing the field of healthcare through its innovative research and production capabilities.Generated from the website

Bioclone Inc., based in San Diego, CA, specializes in providing a wide range of high-quality recombinant proteins and codon-optimized cDNAs for life science research. Their extensive offerings include viral and bacterial antigens, cancer-related proteins, and various purification services using advanced bio-magnetic technologies. In addition to gene synthesis and protein purification, Bioclone offers specialized conjugation services and a variety of magnetic beads tailored for diverse applications. With a commitment to accuracy and rapid turnaround times, they cater to the needs of researchers across multiple disciplines, including drug metabolism, neuroscience, and common disease studies. Generated from the website

Stemedica Cell Technologies, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to the development and commercialization of progenitor cell and protein therapeutics aimed at addressing underserved medical conditions. The company boasts a team of experienced scientists and management, utilizing proprietary technology to produce high-quality progenitor cell products in compliance with stringent standards. Currently, Stemedica is advancing clinical trials in the United States for several critical medical conditions, including chronic ischemic stroke. The company has recently appointed Michael K. Steinhauser as CEO and Interim Chairman, further strengthening its leadership as it initiates Phase IIb/III clinical trials. Generated from the website